Literature DB >> 18682934

Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism.

S F Barrington1, P Anderson, A G Kettle, R Gadd, W H Thomson, S Batchelor, P J Mountford, L K Harding, M J O'Doherty.   

Abstract

OBJECTIVE: The aim of this study was to measure the internal dose received by family members from ingestion of radioactive contamination after outpatient therapy.
MATERIALS AND METHODS: Advice was given to minimise transfer of radioiodine. Home visits were made approximately 2, 7 and 21 days after treatment to measure radioactivity in the thyroids of family members. A decay correction was applied to radioactivity detected assuming ingestion had occurred at the earlier contact time, either the day of treatment or the previous home visit. An effective half-life of 6 or 7 days was used depending on age. Thyroid activity was summed if activity was found at more than one visit in excess of the amount attributable to radioactive decay. Effective dose (ED) was calculated using ICRP72. RESULTS AND DISCUSSION: Fifty-three adults and 92 children, median age 12 (range 4-17) years participated. Median administered activity was 576 (range 329-690) MBq (131)I. Thyroid activity ranged from 0 to 5.4 kBq in the adults with activity detected in 17. Maximum adult ED was 0.4 mSv. Thyroid activity ranged from 0 to 11.8 kBq in the children with activity detected in 26. The two highest values of 5.0 and 11.8 kBq occurred in children aged 5 and 14 years from different families. Eighty-five children had no activity or <1 kBq detected. ED was <0.2 mSv in 86 out of 92 children (93%). Previous published data showed 93% of children received an ED <or=0.8 mSv from external irradiation.
CONCLUSION: With advice, families of outpatients receiving radioiodine should be able to comply with statutory dose limits and constraints.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682934     DOI: 10.1007/s00259-008-0892-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  19 in total

Review 1.  Health effects of the Chernobyl accident: fears, rumours and the truth.

Authors:  Mati Rahu
Journal:  Eur J Cancer       Date:  2003-02       Impact factor: 9.162

2.  Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance.

Authors:  C Reiners; M Lassmann
Journal:  Eur J Nucl Med       Date:  1999-07

3.  Radioiodine therapy to out-patients - the contamination hazard.

Authors:  R C Buchan; J M Brindle
Journal:  Br J Radiol       Date:  1970-07       Impact factor: 3.039

4.  Radioiodine therapy to out-patients--the radiation hazard.

Authors:  R C Buchan; J M Brindle
Journal:  Br J Radiol       Date:  1971-12       Impact factor: 3.039

5.  Risk of thyroid cancer after exposure to 131I in childhood.

Authors:  Elisabeth Cardis; Ausrele Kesminiene; Victor Ivanov; Irina Malakhova; Yoshisada Shibata; Valeryi Khrouch; Vladimir Drozdovitch; Evaldas Maceika; Irina Zvonova; Oleg Vlassov; André Bouville; Guennadi Goulko; Masaharu Hoshi; Alexander Abrosimov; Jadvyga Anoshko; Larisa Astakhova; Sergey Chekin; Evgenyi Demidchik; Rosaria Galanti; Masahiro Ito; Elena Korobova; Evgenyi Lushnikov; Marat Maksioutov; Vladimir Masyakin; Alexander Nerovnia; Vladimir Parshin; Evgenyi Parshkov; Nikolay Piliptsevich; Aldo Pinchera; Semyon Polyakov; Nina Shabeka; Eero Suonio; Vanessa Tenet; Anatoli Tsyb; Shunichi Yamashita; Dillwyn Williams
Journal:  J Natl Cancer Inst       Date:  2005-05-18       Impact factor: 13.506

6.  Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site.

Authors:  Scott Davis; Kenneth J Kopecky; Thomas E Hamilton; Lynn Onstad
Journal:  JAMA       Date:  2004-12-01       Impact factor: 56.272

7.  Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis.

Authors:  M J O'Doherty; A G Kettle; C N Eustance; P J Mountford; A J Coakley
Journal:  Nucl Med Commun       Date:  1993-03       Impact factor: 1.690

8.  Recommended restrictions after 131I therapy: measured doses in family members.

Authors:  I Mathieu; J Caussin; P Smeesters; A Wambersie; C Beckers
Journal:  Health Phys       Date:  1999-02       Impact factor: 1.316

9.  Biokinetics of iodide in man: refinement of current ICRP dosimetry models.

Authors:  L Johansson; S Leide-Svegborn; S Mattsson; B Nosslin
Journal:  Cancer Biother Radiopharm       Date:  2003-06       Impact factor: 3.099

10.  Contamination of the home environment by patients treated with Iodine-131: initial results.

Authors:  A P Jacobson; P A Plato; D Toeroek
Journal:  Am J Public Health       Date:  1978-03       Impact factor: 9.308

View more
  3 in total

1.  Mutagenicity of diagnostic and therapeutical doses of radiopharmaceutical iodine-131 in Wistar rats.

Authors:  Elisângela Düsman; Alessandra Paim Berti; Rosinete Gonçalves Mariucci; Nilson Benedito Lopes; Veronica Elisa Pimenta Vicentini
Journal:  Radiat Environ Biophys       Date:  2011-08-25       Impact factor: 1.925

2.  Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.

Authors:  Klaus Schomäcker; Ferdinand Sudbrock; Thomas Fischer; Markus Dietlein; Carsten Kobe; Mark Gaidouk; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-17       Impact factor: 9.236

3.  Do Current Radiation Safety Guidelines allow the Safe Release of a Thyroid Cancer Patient after High-dose Radioiodine Therapy? An Indian Perspective.

Authors:  Subhash Chand Kheruka; Nilesh Shankar; Manish Ora; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2021-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.